David Wilson, Author at Labiotech.eu

About

David Wilson is an Anglo-Australian business and tech specialist whose experience in journalism spans two decades. His stories have run everywhere from the South China Morning Post to Slate and The New York Times. In the 20-teens he ran a successful rehousing campaign for an extended Vietnamese family of slum-dwellers. In his spare time, he does strength training and hangs out with domestic cats.

Articles by David Wilson

News and Trends 23 Jul 2020

Pharma Giant GSK and mRNA Biotech CureVac Ink €1B Deal

GlaxoSmithKline (GSK) has struck a deal worth up to €1B with the German biotechnology company CureVac to co-develop messenger RNA drugs for infectious diseases. Under the terms of the deal, GSK will fund the development and manufacturing of up to five mRNA-based vaccines and antibody drugs targeting undisclosed infectious diseases. CureVac’s current rabies and Covid-19 […]

July 23, 2020 - 3 minutesmins - By David Wilson

News and Trends 13 Jul 2020

Sanofi Enlists Cell Therapy Firm Kiadis in €875M Immuno-Oncology Deal

The Dutch biotech Kiadis Pharma has licensed an off-the-shelf cell therapy program to the pharma giant Sanofi for up to €857.5M in a deal aiming to develop a combination immunotherapy for the blood cancer multiple myeloma. The preclinical-stage cell therapy that Kiadis licensed is based on genetically modifying donor immune cells called natural killer cells, […]

July 13, 2020 - 3 minutesmins - By David Wilson

News and Trends 13 Jul 2020

Forbion Raises €185M to Fuel Late-Stage European Biotechs

The Dutch life sciences venture capital firm Forbion has bagged €185M in the first closing of a fund aimed at investing in late-stage European biotech companies, which often struggle to raise capital. The main mission of Forbion’s fund — named the Growth Opportunities Fund — is to invest in European life sciences companies raising their […]

July 13, 2020 - 3 minutesmins - By David Wilson

News and Trends 1 Jul 2020

Swiss Regenerative Medicine Biotech Closes €19M Series B

The regenerative medicine startup Cutiss has raised €18.8M (CHF 20M) to commercialize its personalized skin graft treatment for burn patients in Switzerland and the European Union around 2022. This is the final closing of a Series B round announced earlier this month. The lead investor in the oversubscribed round was the Swiss firm Gisev Family […]

July 1, 2020 - 3 minutesmins - By David Wilson

News and Trends 22 Jun 2020

Swedish Biotech’s Psoriasis Drug Beats Placebo in Phase II

A new class of drug developed by the Swedish biotech company Affibody has proved better at treating symptoms of psoriasis than a placebo in a phase II trial, leading the company to develop the candidate for other conditions such as uveitis and psoriatic arthritis. The phase II study enlisted 108 patients with psoriasis, a chronic […]

June 22, 2020 - 3 minutesmins - By David Wilson

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us